Efficacy and safety of escitalopram versus desvenlafaxine in the treatment of major depression: A preliminary 1-year prospective randomized open label comparative trial

Aim and Objective: To compare efficacy and safety of escitalopram with desvenlafaxine in the treatment of major depression. Materials and Methods: A total of 60 patients of depression were randomized into two groups after meeting inclusion criterion. In the first 3 weeks, escitalopram 10 mg/day was given and then 20 mg/day for the next 3 weeks in group 1 \((n = 30)\). Desvenlafaxine in the first 3 weeks was given 50 mg/day and 100 mg/day for the next 3 weeks in group 2 \((n = 30)\). The parameters evaluated during the study were efficacy assessments by Hamilton Scale of Rating Depression (HAM-D), Hamilton Rating Scale of Anxiety (HAM-A), and Clinical Global Impression (CGI). Safety assessments were done by UKU-scale. Results: Escitalopram and desvenlafaxine significantly \((P < 0.001)\), reduced HAM-D, HAM-A, and CGI scores from their respective base lines. However, on comparison failed show any statistical difference at 3 and 6 weeks of treatment. Escitalopram and desvenlafaxine were both found to be safe and well-tolerated and there was not much difference between the two groups as evident from UKU Scale and their effect on various biochemical parameters. Conclusion: The present study demonstrated similar efficacy and safety in reducing depression and anxiety with both escitalopram and desvenlafaxine, but clinical superiority of one drug over the other cannot be concluded due to limitations of the small sample size.

Key words: Anxiety, desvenlafaxine, escitalopram, major depression
attributed to their improved tolerability, ease of use and far greater safety. However, the safety and tolerability of individual SRIs vary within the class and it is clear that many patients may not respond optimally to an acute course of any given treatment. Thus, there is a constant need of search for new better effective treatment.

The efficacy and the tolerability of escitalopram, an SSRI and desvenlafaxine, a non-selective SRI has been well-established. Most of the studies establishing their efficacy and safety are available from western population and whatever available has compared these drugs respectively with placebo. Thus, there are very limited studies available directly comparing efficacies of escitalopram with desvenlafaxine in treatment of major depression.

Hence, a preliminary 1-year prospective randomized open label trial comparing efficacy and safety of escitalopram with desvenlafaxine in the treatment of major depression was undertaken.

**MATERIALS AND METHODS**

A total of 60 patients from psychiatry outpatient department of a tertiary level hospital diagnosed with major depression were included in the study after they fulfilled the inclusion criteria. A total of 30 patients were taken in each group. A written informed consent was obtained from first relative after explaining the nature and purpose of the study along with reverse consent from the patients on their clinical improvement was taken. The study was approved by institutional ethics committee, GMC, Jammu vide number 36A/Pharma/IEC/2010/528 dated 27.10.2010. The flow diagram of the study is shown in Figure 1.

Patients meeting eligibility criteria at the screening visit were assigned randomly in 1:1 ratio to either receive escitalopram or desvenlafaxine. The total duration of study was 6 weeks. The dose of study medication was to be increased after 3 weeks in accordance with the approved labelling information. In the first 3 weeks, escitalopram 10 mg/day was given and then 20 mg/day for the next 3 weeks. Dose of desvenlafaxine in the first 3 weeks was 50 mg/day and 100 mg/day for the next 3 weeks. The primary endpoints were HAM-D, Hamilton Rating Scale of Anxiety (HAM-A), and Clinical Global Impression (CGI).

**Exclusion criteria**

Patients with the following conditions were excluded from the study - those taking any antidepressant in the last 6 weeks; intake of any drug which may causes depressive state, psychosis or anxiety; any chronic ailment; any substance abuse; and those patients intolerant or allergic to the drug.

Adverse event monitoring was done by using UKU-scale. Furthermore, some of biochemical parameter like blood sugar, LFT, and RFT were also analyzed and compared among two treatment arms for safety assessment.

**Statistical analysis**

All the analysis was carried out with the help of computer software SPSS version 15 for windows. The evaluation of patients in two groups was done by applying HAM-D, HAM-A, and CGI and will be reported as mean ± standard deviation scores. The score were reported as % change from

---

**Figure 1: Study flow diagram**

Patients meeting eligibility criteria at the screening visit were assigned randomly in 1:1 ratio to either receive escitalopram or desvenlafaxine. The total duration of study was 6 weeks. The dose of study medication was to be increased after 3 weeks in accordance with the approved labelling information. In the first 3 weeks, escitalopram 10 mg/day was given and then 20 mg/day for the next 3 weeks. Dose of desvenlafaxine in the first 3 weeks was 50 mg/day and 100 mg/day for the next 3 weeks. The primary endpoints were HAM-D, Hamilton Rating Scale of Anxiety (HAM), and Clinical Global Impression (CGI).
the baseline and were assessed by use of paired/unpaired "t" test/analysis of covariance whichever was applicable. Categorical variables were reported as percentage and the statistical analysis done by use of Chi-square test. A $P < 0.05$ was considered statistically significant. All $P$ values reported analyses were two-tailed. The analysis was done on intention-to-treat basis.

**RESULTS**

The base line parameters of both the group has been shown in Table 1. Both escitalopram as well as desvenlafaxine significantly ($P < 0.001$) reduced HAM-D, HAM-A, and CGI scores from their respective base lines [Table 2]. However, on comparison failed show any statistical difference at 3 and 6 weeks of treatment [Table 3].

Escitalopram and desvenlafaxine were both safe and well-tolerated and there was not much difference between the two groups as evident from UKU-scale [Table 4].

Escitalopram and desvenlafaxine were both safe and well-tolerated and there was not much difference between the two groups as far the effect on various biochemical parameters was concerned [Table 5].

Side effects seen in the present study with escitalopram were headache ($n = 6$), nausea ($n = 4$), vomiting ($n = 1$), diarrhea ($n = 2$), palpitations ($n = 3$), sexual dysfunction

---

**Table 1: Baseline characteristics of patients (mean±standard deviation)**

| Parameter | Escitalopram mean±SD | Desvenlafaxine mean±SD | Statistical inference |
|-----------|-----------------------|-------------------------|----------------------|
| Age (years) | 34.23±9.19 | 33.60±9.95 | $t = 0.25$, $P = 0.79$ |
| Gender: Male: Female | 13:17 | 15:15 | $\chi^2 = 0.27$, $P = 0.60$ |
| HAM-D | 23.96±2.20 | 23.66±2.07 | $t = 0.54$, $P = 0.58$ |
| HAM-A | 14.56±3.35 | 14.96±2.77 | $t = -0.50$, $P = 0.61$ |
| CGI | 5.76±0.67 | 5.56±0.77 | $t = 1.06$, $P = 0.29$ |
| Pulse | 81.53±5.47 | 82.50±7.97 | $t = -0.54$, $P = 0.58$ |
| BP systolic mm/hg | 124.93±3.31 | 125.40±4.30 | $t = -0.47$, $P = 0.64$ |
| BP diastolic mm/hg | 79.66±8.08 | 80.63±9.08 | $t = -0.22$, $P = 0.62$ |
| Weight (kg) | 65.23±11.99 | 65.93±12.45 | $t = 0.27$, $P = 0.60$ |
| Height (cm) | 166.56±9.34 | 166.86±8.70 | $t = 0.12$, $P = 0.89$ |
| BMI (kg/m²) | 23.34±2.48 | 23.60±3.24 | $t = 0.35$, $P = 0.72$ |
| Waist circumference | 81.90±6.65 | 80.96±9.08 | $t = 0.45$, $P = 0.65$ |
| Blood sugar (R) | 107.96±3.47 | 105.90±5.26 | $t = 1.79$, $P = 0.07$ |
| Serum urea (mg/dl) | 32.43±12.03 | 31.60±2.54 | $t = 0.90$, $P = 0.36$ |
| Serum creatinine (mg/dl) | 34.06±10.27 | 32.06±7.07 | $t = 0.78$, $P = 0.43$ |
| Serum sodium (mEq/L) | 11.24±0.89 | 11.28±0.96 | $t = 0.35$, $P = 0.72$ |
| Serum potassium (mEq/L) | 4.22±0.24 | 4.24±0.10 | $t = 0.12$, $P = 0.90$ |
| Serum bilirubin (mg/dl) | 0.81±0.07 | 0.82±0.04 | $t = 0.12$, $P = 0.90$ |
| SGOT (IU/L) | 32.43±4.32 | 31.60±2.54 | $t = 0.90$, $P = 0.36$ |
| SGPT (IU/L) | 34.06±12.03 | 32.06±7.07 | $t = 0.78$, $P = 0.43$ |
| Total WBC/cumm | 6066.66±784.91 | 5666.66±606.47 | $t = 2.20$, $P = 0.03$ |
| Platelet count lakh/cumm | 1.90±0.173 | 1.91±0.178 | $t = 0.21$, $P = 0.83$ |

BP=Blood pressure, BMI=Body mass index, CGI=Clinical global impression, HAM-A=Hamilton rating scale of anxiety, HAM-D=Hamilton scale of rating depression, Hb=hemoglobin, SD=Standard deviation, SGPT=Serum glutamate pyruvate transaminase, SGOT=Serum glutamate oxaloacetate trasnaminase , WBC=White blood cell

---

**Table 2: Effect of treatment across escitalopram ($n=30$) and desvenlafaxine ($n=30$) groups over time: Scores within subjects (mean±standard deviation)**

| Variables | 0 week | 3rd week | 6th week | Pillai’s trace F (within subjects) | $P$ value |
|-----------|--------|----------|----------|-----------------------------------|-----------|
| HAM-D total score | 23.97±2.21 | 19.70±1.91 | 16.30±1.57 | 490.94 | <0.001* |
| Escitalopram | 23.67±2.07 | 20±4.19 | 17.1±3.52 | 342.1 | <0.001* |
| Desvenlafaxine | 14.57±3.56 | 11.87±3.17 | 9.63±3.02 | 420.88 | <0.001* |
| CGI | 5.75±0.77 | 2.93±0.31 | 2.47±0.51 | 2.53±0.57 | <0.001* |

*P<0.05=Significant (two-tailed), CGI=Clinical global impression, HAM-A=Hamilton rating scale of anxiety, HAM-D=Hamilton scale of rating depression
Table 3: Effect of treatment across escitalopram (n=30) and desvenlafaxine (n=30) groups over time: Scores between subjects (mean±standard deviation)

| Variables      | 1st week | 2nd week | 3rd week | 6th week | Pillai’s trace F (within subjects) | P value |
|----------------|----------|----------|----------|----------|-----------------------------------|---------|
| HAM-D score    |          |          |          |          |                                   |         |
| Escitalopram   | 23.97±2.21 | 19.70±1.91 | 16.30±1.57 | 3.014 | 0.057 |
| Desvenlafaxine | 23.67±2.07 | 20±4.19 | 17.1±3.52 |         |         |
| HAM-A score    |          |          |          |          |                                   |         |
| Escitalopram   | 14.57±3.56 | 11.87±3.17 | 9.63±3.02 | 2.596 | 0.083 |
| Desvenlafaxine | 14.97±2.77 | 11.9±3.49 | 9.17±3.11 |         |         |
| CGI score      |          |          |          |          |                                   |         |
| Escitalopram   | 5.77±0.68 | 2.90±0.31 | 2.47±0.51 | 0.754 | 0.475 |
| Desvenlafaxine | 5.57±0.77 | 2.93±0.25 | 2.53±0.57 |         |         |

*P=0.05=Significant (two-tailed). CGI: Clinical Global Impression, HAM-A: Hamilton Rating Scale of Anxiety, HAM-D: Hamilton Scale of Rating Depression

Table 4: Effect of escitalopram (n=30) and desvenlafaxine (n=30) On UKU scale at 6 weeks

| Parameter     | Escitalopram | Desvenlafaxine | Statistical inference |
|---------------|--------------|----------------|----------------------|
| UKU mean±SD   | 0.93         | 1.13           | 0.96                 |
| SD            | 0.66         | 0.36           | 0.33                 |

SD=Standard deviation, UKU=Udvalg for kliniske undersøgelser

(n=1), loss of appetite (n=1), insomnia (n=3), and constipation (n=1). Whereas, with desvelafaxine were headache (n=4), nausea (n=9), palpitations (n=2), insomnia (n=3), constipation (n=3), giddiness (n=4), dry mouth (n=3), and restlessness (n=1).

DISCUSSION

In the present study, it was seen that escitalopram-reduced depression levels with a decrease from the baseline value HAM-D from 3 weeks onward till the end of the study. The above findings are in concurrence with various published reports in which these drugs, individually were efficacious in decreasing depression and anxiety in comparison to placebo.

A similar reduction in depression by escitalopram is also reported by Burke et al.
who showed that escitalopram significantly improved MADRS scores in comparison to placebo starting with in within one week of treatment and persisting till 8 weeks of therapy at both the doses (10 mg and 20 mg).

Rapaport et al. showed that the time to depression relapse was significantly longer (P=0.013) and the cumulative rate of relapse was significantly lower in patients who received escitalopram (26% escitalopram vs. 40% placebo; hazard ratio = 0.56; P = 0.01). Moore et al. showed that the Montgomery-Åsberg Depression Rating Scale (MADRS) score decreased more in the escitalopram than in the citalopram arm (–22.4 ± 12.9 vs. –20.3 ± 12.7; P < 0.05). There were more treatment responders with escitalopram (76.1%) than with citalopram (61.3%, P < 0.01).

In the present study, it was seen that desvenlafaxine produced a decrease from the baseline value of HAM-D from 3 weeks onward till the end of the study, that is, at 6 weeks. Desvenlafaxine has also been shown to cause a significant reduction in depression in several studies.

These studies found out that mean HAM-D scores for desvenlafaxine 50, 100, 200, and 400 mg/day were significantly lower than placebo, respectively.

In the present study, there was a trend toward the higher overall response of escitalopram in decreasing depression and anxiety than with desvenlafaxine (F= 3.014, P = 0.057). Our results are almost in accordance to those put forth by Soares et al., who reported a similar reduction in depression with escitalopram and desvenlafaxine. Reductions in HAM-D total score at acute phase end point were similar for desvenlafaxine and escitalopram-treated women (-13.6 vs. 14.3, respectively, P = 0.24). No significant difference was observed between groups at continuation phase end points in the proportion of who maintained response (desvenlafaxine, 82%; escitalopram, 80%, P = 0.70).

Limited studies have directly compared the efficacies of escitalopram and desvenlafaxine in treatment of major depression, otherwise escitalopram has been compared with class SNRI's in other studies. Kornstein et al. showed that mean reduction in MADRS score from baseline to week 8 was significantly greater for the escitalopram group versus the SNRI group.

In the present study, it was seen that escitalopram produced a decrease from the baseline value of HAM-A, from 3 weeks onward till the end of the study, that is, at
Table 5: Effect of escitalopram (n=30) and desvenlafaxine (n=30) on various biochemical parameters (mean±standard deviation)

| Variables          | 1st week | 3rd week | 6th week | Pillai’s trace F (within subjects) | P value |
|--------------------|----------|----------|----------|------------------------------------|---------|
| Blood sugar        |          |          |          |                                    |         |
| Escitalopram       | 107.96±3.47 | 105.50±5.45 | 107.56±5.40 | 0.697                               | 0.502   |
| Desvenlafaxine     | 105.90±5.26 | 105±4.41  | 105.03±4.58 |                                     |         |
| Serum urea         |          |          |          |                                    |         |
| Escitalopram       | 27.83±1.085 | 27.96±0.61  | 28.03±1.03  | 1.874                               | 0.163   |
| Desvenlafaxine     | 28.16±0.69  | 28.13±0.77 | 28±0.69    |                                     |         |
| Serum creatinine   |          |          |          |                                    |         |
| Escitalopram       | 0.58±0.092  | 0.56±0.071  | 0.58±0.089  | 0.311                               | 0.734   |
| Desvenlafaxine     | 0.57±0.053  | 0.56±0.062  | 0.56±0.061  |                                     |         |
| Desvenlafaxine     | 5.57±0.77   | 2.93±0.25   | 2.53±0.57   |                                     |         |
| Serum bilirubin    |          |          |          |                                    |         |
| Escitalopram       | 0.81±0.073  | 0.81±0.07   | 0.82±0.04   | 0.020                               | 0.981   |
| Desvenlafaxine     | 0.82±0.061  | 0.83±0.047  | 0.83±0.047  |                                     |         |
| Serum SGOT         |          |          |          |                                    |         |
| Escitalopram       | 32.43±4.32  | 31.66±2.46  | 32.70±4.12  | 0.301                               | 0.741   |
| Desvenlafaxine     | 31.20±2.60  | 32.86±2.08  | 32.86±2.08  |                                     |         |
| Desvenlafaxine     | 5.57±0.77   | 2.93±0.25   | 2.53±0.57   |                                     |         |
| Serum SGPT         |          |          |          |                                    |         |
| Escitalopram       | 34.06±12.034 | 32.36±7.07  | 32.30±6.43  | 0.207                               | 0.814   |
| Desvenlafaxine     | 32.06±7.07  | 32.53±8.01  | 31.60±6.41  |                                     |         |

*P<0.05=Significant (two-tailed). SGPT=Serum glutamate pyruvate transaminase, SGOT=Serum glutamate oxaloacetate trasnaminase

6 weeks indicating additional anxiolytic activity. Similar reductions in anxiety by escitalopram were put forth by Malin et al.[16] who consistently demonstrated significant anxiolytic properties in addition to antidepressant efficacy with escitalopram. It also showed efficacy in treating panic disorder and generalized and social anxiety disorders.

Bandelow et al.[17] documented the efficacy of escitalopram on symptoms of anxiety in patients with major depressive disorder. Similarly, escitalopram was shown significantly more effective compared to placebo in treating both anxiety symptoms and the entire depression in the total depressive population, as well as in depressive patients with a high degree of anxiety by Cyril and Jaromir.[18]

In the present study, it was seen that desvenlafaxine also produced a decrease from the respective baseline value of CGI from 3 weeks onward till the end of the study, that is, at 6 weeks. A similar reduction in CGI by escitalopram is also reported by Olić et al.,[20] and Yevtushenko et al.[21]

In the present study, it was seen that desvenlafaxine also produced a decrease from the respective baseline value of CGI from 3 weeks onward till the end of the study, that is, at 6 weeks. Similar reductions in CGI were seen in other studies also.[14,19]

In current study, there is no significant difference in the CGI scores of escitalopram group and desvenlafaxine group (P = 0.475) Scores between subjects. Similar results were seen by Soares et al.,[14] with almost same reduction in both escitalopram and desvenlafaxine group.

In the present study, escitalopram and desvenlafaxine were safe and well-tolerated. UKU scale is used to evaluate side effects and the values are (0.93 and 1.13), respectively in escitalopram and desvenlafaxine group. There is no statistically significant difference between the two groups (t=0.96, P = 0.33). There was no other discontinuation due to any other reasons including adverse effects in the present study. Similar side effect profile was put forth by Soares et al.,[14] who showed both desvenlafaxine and escitalopram were generally safe and well-tolerated.

The present study does have some limitations. First, it is a short-term study with less number of patients and effect of small sample size cannot be ruled out on results of the study.
CONCLUSION

The present study demonstrated almost similar efficacy and safety in reducing depression and anxiety with both escitalopram and desvenlafaxine, but clinical superiority of one drug over the other cannot be definitely be concluded due to small sample size. Escitalopram and desvenlafaxine were well-tolerated.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

1. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997;349:1498-504.
2. Oliver JS, Burrows GD, Norman TR. Third generation antidepressants; do they offer advantages over the SSRIs? CNS Drugs 2001;15:941-54.
3. Pavot S, Judge R, Hindmarch I. Safety and tolerability considerations: Tricyclic antidepressants vs selective serotonin reuptake inhibitors. Acta Psychiatr Scand Suppl 2000;403:17-25.
4. American Psychiatric Association, Diagnostic and Statistical Manual of mental Disorders. 4th ed. Washington: American Psychiatry Association; 1994.
5. Hamilton M. A rating for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
6. Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002;63:331-6.
7. Leopolo UM, Loft H, Reines EH. Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2003;18:211-7.
8. Rapaport MH, Bose A, Zheng H. Escitalopram continuation treatment prevents relapse of depressive episodes. J Clin Psychiatry 2004;65:44-9.
9. Moore N, Verdonck H, Fantino B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder”. Int Clin Psychopharmacol 2005;20:131-7.
10. DeMartinis NA, Yeung P, Entsua R, Manley AL. A double blind placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry 2007;68:677-88.
11. Septien-Veleza L, Pitroska B, Padmanabhan SK, Germain JM, Tourian KA. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder. Int Clin Psychopharmacol 2007;22:338-47.
12. Liebowitz MR, Manley AL, Padmanandam SK, Ganguly R, Tummala R, Tourian KA. Efficacy, safety, and tolerability of desvenlafaxine 50mg/day and 100mg/day in outpatients with major depressive disorder. Cur Med Res Opin 2008;24:1877-90.
13. Boyer P, Montgomery SA, Lepola U, Germain JM, Brisard C, Ganguly R, et al. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol 2008;23:243-53.
14. Soares CN, Thase ME, Clayton A, Guico-Fabia CJ, Focht K, Jiang Q, et al. Desvenlafaxine and escitalopram for the treatment of postmenopausal women with major depressive disorder. Menopause 2010;17:700-11.
15. Kornstein SG, Bose A, Dayongli, Saikali KG, Gandhi C. Escitalopram maintenance treatment for prevention of recurrent depression: A randomized, placebo-controlled trial. J Clin Psychiatry 2006;67:1767-75.
16. Malin PJ, Wengel, SP, Burke WJ. Escitalopram: Better treatment for depression is through the looking glass. Expert Rev Neurother 2004;4:769-79.
17. Bandelow B, Andersen HF, Dolberg OT. Escitalopram in the treatment of anxiety symptoms associated with depression. Depress Anxiety 2007;24:53-61.
18. Höschl C, Svestka J. Escitalopram for the treatment of major depression and anxiety disorders. Expert Rev Neurother 2008;8:537-52.
19. Tourian KA, Jiang Q, Ninan PT. Analysis of the effect of desvenlafaxine on anxiety symptoms associated with major depressive disorder. Pooled Data from 9 short-term, double-blind, placebo-controlled trials. CNS Spectra 2010;15:187-93.
20. Olié JP, Tonnoir B, Ménard F, Galinowski A. A prospective study of escitalopram in the treatment of major depressive episodes in the presence or absence of anxiety. Depress Anxiety 2007;24:318-24.
21. Yevtushenko VY, Belous AI, Yevgenia G. Efficacy and tolerability of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry 2010;71:449-56.

Author Help: Reference checking facility

The manuscript system (www.journalonweb.com) allows the authors to check and verify the accuracy and style of references. The tool checks the references with PubMed as per a predefined style. Authors are encouraged to use this facility, before submitting articles to the journal.

- The style as well as bibliographic elements should be 100% accurate, to help get the references verified from the system. Even a single spelling error or addition of issue number/month of publication will lead to an error when verifying the reference.
- Example of a correct style
  Sheahan P, O’leary G, Lee G, Fitzibbon J. Cystic cervical metastases: Incidence and diagnosis using fine needle aspiration biopsy. Otolaryngol Head Neck Surg 2002;127:294-8.
- Only the references from journals indexed in PubMed will be checked.
- Enter each reference in new line, without a serial number.
- Add up to a maximum of 15 references at a time.
- If the reference is correct for its bibliographic elements and punctuations, it will be shown as CORRECT and a link to the correct article in PubMed will be given.
- If any of the bibliographic elements are missing, incorrect or extra (such as issue number), it will be shown as INCORRECT and link to possible articles in PubMed will be given.